WallStreetZenWallStreetZen

NASDAQ: KTTA
Pasithea Therapeutics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KTTA

Based on 1 analyst offering 12 month price targets for Pasithea Therapeutics Corp

Min Forecast
$3.00+289.61%
Avg Forecast
$3.00+289.61%
Max Forecast
$3.00+289.61%

Should I buy or sell KTTA stock?

Based on 1 analyst offering ratings for Pasithea Therapeutics Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KTTA stock forecasts and price targets.

KTTA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-12-08

1 of 1

Forecast return on equity

Is KTTA forecast to generate an efficient return?

Company
-40.08%
Industry
41.96%
Market
161.65%
KTTA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KTTA forecast to generate an efficient return on assets?

Company
-36.74%
Industry
8.64%
KTTA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KTTA earnings per share forecast

What is KTTA's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.69
Avg 2 year Forecast
-$0.84
Avg 3 year Forecast
-$0.89

KTTA revenue forecast

What is KTTA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

KTTA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KTTA$0.77$3.00+289.61%Buy
JSPR$0.69$4.17+505.67%Hold
CTXR$0.85$6.00+602.58%Strong Buy
PLRZ$12.08N/AN/A
TVGN$4.46$100.00+2,142.15%Strong Buy
View Top Biotech Stocks

Pasithea Therapeutics Stock Forecast FAQ

Is Pasithea Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: KTTA) stock is to Buy KTTA stock.

Out of 1 analyst, 0 (0%) are recommending KTTA as a Strong Buy, 1 (100%) are recommending KTTA as a Buy, 0 (0%) are recommending KTTA as a Hold, 0 (0%) are recommending KTTA as a Sell, and 0 (0%) are recommending KTTA as a Strong Sell.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.

What is KTTA's earnings growth forecast for 2026-2028?

(NASDAQ: KTTA) Pasithea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 75.84%.

Pasithea Therapeutics's earnings in 2026 is -$20,427,683.On average, 3 Wall Street analysts forecast KTTA's earnings for 2026 to be -$17,298,348, with the lowest KTTA earnings forecast at -$16,619,981, and the highest KTTA earnings forecast at -$17,807,123. On average, 3 Wall Street analysts forecast KTTA's earnings for 2027 to be -$20,859,773, with the lowest KTTA earnings forecast at -$20,041,742, and the highest KTTA earnings forecast at -$21,473,295.

In 2028, KTTA is forecast to generate -$22,131,710 in earnings, with the lowest earnings forecast at -$21,263,800 and the highest earnings forecast at -$22,782,642.

What is KTTA's revenue growth forecast for 2026-2028?

(NASDAQ: KTTA) Pasithea Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 54.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.62%.

Pasithea Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast KTTA's revenue for 2026 to be $0, with the lowest KTTA revenue forecast at $0, and the highest KTTA revenue forecast at $0. On average, 3 Wall Street analysts forecast KTTA's revenue for 2027 to be $0, with the lowest KTTA revenue forecast at $0, and the highest KTTA revenue forecast at $0.

In 2028, KTTA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KTTA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KTTA) forecast ROA is -36.74%, which is lower than the forecast US Biotechnology industry average of 8.64%.

What is KTTA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KTTA price target, the average KTTA price target is $3.00, with the highest KTTA stock price forecast at $3.00 and the lowest KTTA stock price forecast at $3.00.

The Wall Street analyst predicted that Pasithea Therapeutics's share price could reach $3.00 by Dec 8, 2026. The average Pasithea Therapeutics stock price prediction forecasts a potential upside of 289.61% from the current KTTA share price of $0.77.

What is KTTA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KTTA) Pasithea Therapeutics's current Earnings Per Share (EPS) is -$2.91. On average, analysts forecast that KTTA's EPS will be -$0.69 for 2026, with the lowest EPS forecast at -$0.67, and the highest EPS forecast at -$0.71. On average, analysts forecast that KTTA's EPS will be -$0.84 for 2027, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.86. In 2028, KTTA's EPS is forecast to hit -$0.89 (min: -$0.85, max: -$0.91).

What is KTTA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KTTA) forecast ROE is -40.08%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.